AbbVie Inc.ABBV
AbbVie Inc. Segments Disclosure
Segment and Geographic Area Information
Net revenues to external customers by geographic area, based on product shipm
AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as Chief Operating Decision Maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.
The CODM regularly reviews net revenues, net earnings and significant segment expenses and uses net earnings as its principal measure of segment profit or loss. Net earnings and significant segment expenses reviewed by CODM are reported on the consolidated statement of earnings for the years ended December 31, 2025, 2024 and 2023. The CODM uses net earnings as its principal measure of segment profit or loss to compare past financial performance with current performance and analyze underlying business performance and trends. The CODM does not use segment assets to make decisions regarding resources; therefore, the total asset disclosure has not been included.
Substantially all of AbbVie's pharmaceutical product net revenues in the United States are to three wholesalers. Outside the United States, products are sold primarily to health care providers or through distributors, depending on the market served. The following tables detail AbbVie's worldwide net revenues:
| years ended December 31 (in millions) | 2025 | 2024 | 2023 | |||||||||||||||||
| Immunology | ||||||||||||||||||||
| Skyrizi | United States | $ | 15,202 | $ | 10,086 | $ | 6,753 | |||||||||||||
| International | 2,360 | 1,632 | 1,010 | |||||||||||||||||
| Total | $ | 17,562 | $ | 11,718 | $ | 7,763 | ||||||||||||||
| Rinvoq | United States | $ | 5,940 | $ | 4,259 | $ | 2,824 | |||||||||||||
| International | 2,364 | 1,712 | 1,145 | |||||||||||||||||
| Total | $ | 8,304 | $ | 5,971 | $ | 3,969 | ||||||||||||||
| Humira | United States | $ | 3,062 | $ | 7,142 | $ | 12,160 | |||||||||||||
| International | 1,478 | 1,851 | 2,244 | |||||||||||||||||
| Total | $ | 4,540 | $ | 8,993 | $ | 14,404 | ||||||||||||||
| Neuroscience | ||||||||||||||||||||
Vraylar | United States | $ | 3,612 | $ | 3,260 | $ | 2,755 | |||||||||||||
| International | 9 | 7 | 4 | |||||||||||||||||
| Total | $ | 3,621 | $ | 3,267 | $ | 2,759 | ||||||||||||||
Botox Therapeutic | United States | $ | 3,151 | $ | 2,718 | $ | 2,476 | |||||||||||||
| International | 618 | 565 | 515 | |||||||||||||||||
| Total | $ | 3,769 | $ | 3,283 | $ | 2,991 | ||||||||||||||
Ubrelvy | United States | $ | 1,239 | $ | 981 | $ | 803 | |||||||||||||
| International | 32 | 25 | 12 | |||||||||||||||||
| Total | $ | 1,271 | $ | 1,006 | $ | 815 | ||||||||||||||
Qulipta | United States | $ | 906 | $ | 628 | $ | 405 | |||||||||||||
| International | 130 | 30 | 3 | |||||||||||||||||
| Total | $ | 1,036 | $ | 658 | $ | 408 | ||||||||||||||
Vyalev | United States | $ | 167 | $ | 1 | $ | — | |||||||||||||
| International | 315 | 98 | 3 | |||||||||||||||||
| Total | $ | 482 | $ | 99 | $ | 3 | ||||||||||||||
| Duodopa | United States | $ | 73 | $ | 96 | $ | 97 | |||||||||||||
| International | 308 | 351 | 371 | |||||||||||||||||
| Total | $ | 381 | $ | 447 | $ | 468 | ||||||||||||||
| years ended December 31 (in millions) | 2025 | 2024 | 2023 | |||||||||||||||||
Other Neuroscience | United States | $ | 192 | $ | 223 | $ | 254 | |||||||||||||
| International | 15 | 16 | 19 | |||||||||||||||||
| Total | $ | 207 | $ | 239 | $ | 273 | ||||||||||||||
| Oncology | ||||||||||||||||||||
| Imbruvica | United States | $ | 2,048 | $ | 2,448 | $ | 2,665 | |||||||||||||
| 821 | 899 | 931 | ||||||||||||||||||
| Total | $ | 2,869 | $ | 3,347 | $ | 3,596 | ||||||||||||||
| Venclexta | United States | $ | 1,306 | $ | 1,234 | $ | 1,087 | |||||||||||||
| International | 1,486 | 1,349 | 1,201 | |||||||||||||||||
| Total | $ | 2,792 | $ | 2,583 | $ | 2,288 | ||||||||||||||
| Elahere | United States | $ | 607 | $ | 477 | $ | — | |||||||||||||
| International | 83 | 2 | — | |||||||||||||||||
| Total | $ | 690 | $ | 479 | $ | — | ||||||||||||||
| Epkinly | $ | 181 | $ | 118 | $ | 28 | ||||||||||||||
| International | 90 | 28 | 3 | |||||||||||||||||
| Total | $ | 271 | $ | 146 | $ | 31 | ||||||||||||||
| Other Oncology | United States | $ | 33 | $ | — | $ | — | |||||||||||||
| Aesthetics | ||||||||||||||||||||
Botox Cosmetic | United States | $ | 1,504 | $ | 1,682 | $ | 1,670 | |||||||||||||
| International | 1,098 | 1,038 | 1,012 | |||||||||||||||||
| Total | $ | 2,602 | $ | 2,720 | $ | 2,682 | ||||||||||||||
Juvederm Collection | United States | $ | 385 | $ | 469 | $ | 519 | |||||||||||||
| International | 608 | 708 | 859 | |||||||||||||||||
| Total | $ | 993 | $ | 1,177 | $ | 1,378 | ||||||||||||||
Other Aesthetics | United States | $ | 1,101 | $ | 1,118 | $ | 1,060 | |||||||||||||
| International | 164 | 161 | 174 | |||||||||||||||||
| Total | $ | 1,265 | $ | 1,279 | $ | 1,234 | ||||||||||||||
| Eye Care | ||||||||||||||||||||
| Ozurdex | United States | $ | 124 | $ | 138 | $ | 143 | |||||||||||||
| International | 369 | 356 | 329 | |||||||||||||||||
| Total | $ | 493 | $ | 494 | $ | 472 | ||||||||||||||
Lumigan/Ganfort | United States | $ | 189 | $ | 187 | $ | 173 | |||||||||||||
| International | 221 | 242 | 259 | |||||||||||||||||
| Total | $ | 410 | $ | 429 | $ | 432 | ||||||||||||||
Alphagan/Combigan | United States | $ | 53 | $ | 95 | $ | 121 | |||||||||||||
| International | 144 | 153 | 151 | |||||||||||||||||
| Total | $ | 197 | $ | 248 | $ | 272 | ||||||||||||||
Other Eye Care | United States | $ | 588 | $ | 644 | $ | 815 | |||||||||||||
| International | 421 | 427 | 424 | |||||||||||||||||
| Total | $ | 1,009 | $ | 1,071 | $ | 1,239 | ||||||||||||||
| Other Key Products | ||||||||||||||||||||
| Mavyret | United States | $ | 635 | $ | 595 | $ | 659 | |||||||||||||
| International | 682 | 716 | 771 | |||||||||||||||||
| Total | $ | 1,317 | $ | 1,311 | $ | 1,430 | ||||||||||||||
| Creon | United States | $ | 1,512 | $ | 1,383 | $ | 1,268 | |||||||||||||
Linzess/Constella | United States | $ | 864 | $ | 916 | $ | 1,073 | |||||||||||||
| International | 43 | 38 | 35 | |||||||||||||||||
| Total | $ | 907 | $ | 954 | $ | 1,108 | ||||||||||||||
| All other | $ | 2,627 | $ | 3,032 | $ | 3,035 | ||||||||||||||
| Total net revenues | $ | 61,160 | $ | 56,334 | $ | 54,318 | ||||||||||||||
ent destination, were as follows:
| years ended December 31 (in millions) | 2025 | 2024 | 2023 | ||||||||||||||
| United States | $ | 46,603 | $ | 43,029 | $ | 41,883 | |||||||||||
| Germany | 1,738 | 1,465 | 1,266 | ||||||||||||||
| Japan | 1,274 | 1,122 | 1,008 | ||||||||||||||
| Canada | 1,222 | 1,088 | 1,076 | ||||||||||||||
| China | 1,006 | 917 | 950 | ||||||||||||||
| France | 806 | 776 | 780 | ||||||||||||||
| United Kingdom | 626 | 522 | 417 | ||||||||||||||
| Spain | 609 | 528 | 501 | ||||||||||||||
| Italy | 580 | 511 | 484 | ||||||||||||||
| Brazil | 478 | 464 | 439 | ||||||||||||||
| Australia | 459 | 463 | 472 | ||||||||||||||
| All other countries | 5,759 | 5,449 | 5,042 | ||||||||||||||
| Total net revenues | $ | 61,160 | $ | 56,334 | $ | 54,318 | |||||||||||
See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 7), intangible assets impairment expense (Note 7), change in fair value of contingent consideration (Note 11), interest income and expense (Note 3), depreciation expense (Note 2), litigation matters (Note 15), income tax expense (Note 14) and restructuring expense (Note 8).
Long-lived assets, consisting of property and equipment, net, by geographic area were as follows:
| as of December 31 (in millions) | 2025 | 2024 | |||||||||
United States | $ | 3,404 | $ | 3,331 | |||||||
| Europe | 1,804 | 1,485 | |||||||||
| All other | 420 | 318 | |||||||||
| Total long-lived assets | $ | 5,628 | $ | 5,134 | |||||||
Free Sentinel
Track for freeWant the next AbbVie Inc. segments disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment AbbVie Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 20, 2026 | Showing above |
| 2024 | Feb 14, 2025 | |
| 2023 | Feb 20, 2024 | |
| 2022 | Feb 17, 2023 | |
| 2021 | Feb 18, 2022 | |
| 2020 | Feb 19, 2021 | |
| 2019 | Feb 21, 2020 | |
| 2018 | Feb 27, 2019 | |
| 2017 | Feb 16, 2018 | |
| 2016 | Feb 17, 2017 | |
| 2015 | Feb 19, 2016 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.